Diametrics Medical Inc plans to be profitable by the third quarter and generate revenues of . million this year, million in and million in , said chief executive David Giddings. Our objective is to have our first profitable quarter in the third quarter of ' , Giddings said in an interview with Reuters at a Dain Bosworth conference here on Wednesday. He said Diametrics a maker of hospital bedside blood gas analysis systems has failed to deliver on its promises in the past, but he added, That wasn't on my watch. Diametrics reported a year end loss of million. The company expects to launch its new IRMA SL blood gas analyzer system this month. The way the market should judge us is by what we do over the next three months, he said. He added that the company has several options before it in the way of possible corporate alliances. The IRMA is a portable, four pound instrument that measures blood levels of oxygen, acidity, carbon dioxide, electrolytes and red blood cell volume much faster than competing systems requiring analysis to be done in the hospital laboratory. The SL version adds features not seen in older models. Shares in Diametrics were up at . One year ago, Diametric shares traded as high as , but delays in delivering new products wrecked Wall Street forecasting models and the stock suffered. Giddings started with six year old Diametrics in April after a management shake up prompted by the company's failure to move beyond the research and development phase. Shortly after arriving, Giddings pushed through an percent workforce cut and said Wednesday he would not rule out the possibility of further cuts, depending on results. The Roseville, Minn. based company's work force now numbers people, down from . We have a goal of being profitable in the third quarter of and we will do what it takes to hit that objective in terms of our cost base, Giddings said. 